on Pentixapharm Holding AG (ETR:PTP)
Pentixapharm Reports 9-Month Financial Results for 2025
Berlin-based biotech firm Pentixapharm Holding AG has released its financial results for the first nine months of 2025. The company recorded a loss of €12.7 million, primarily due to research and development, personnel, and operational expenses. During this period, revenue was reported at €117,000.
The total balance sheet as of September 30, 2025, stood at €43 million. The Executive Board has revised the full-year loss guidance to approximately €18 million, down from the previously projected €23.5 million. This forecast considers R&D and operational expenses but does not include potential earnings from out-licensing.
Full financial details are accessible on the Pentixapharm Investor Relations site.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Pentixapharm Holding AG news